Publicação

Does baseline total testosterone improve the yielding of prostate cancer screening?

Ver documento

Detalhes bibliográficos
Resumo:Previous studies suggest an association between total testosterone (tT) and prostate cancer, but results are conflicting and it is not clear if accounting for the tT levels improves the yielding of patient selection for prostatic biopsy. We evaluated the potential for tT levels and the tT/total PSA (tPSA) ratio to be used as diagnostic tools for prostate cancer and its relation with cancer aggressiveness. We measured tT, tPSA and free PSA (fPSA) in fasting blood samples of 1570 subjects consecutively referred for prostate biopsy due to abnormal digital rectal examination and/or elevated tPSA levels. These values were compared between groups defined according to the pathological results of the biopsy. No significant difference was observed in tT levels when comparing cases with prostate cancer, high grade prostate intraepithelial neoplasia, pathological prostatitis, benign prostatic hyperplasia or no alteration (median: 4.26 versus 4.44 versus 4.31 versus 4.16 pg/mL, respectively; p=0.643). The tT/tPSA ratio had a better area under the curve than tT alone (0.62, 95% CI, 0.59-0.65 versus 0.50, 95% CI, 0.47-0.53), but worse than the f/tPSA ratio (0.70, 95% CI, 0.67-0.73). In multivariate analysis, using the median of distribution as cut-off no significant association was observed between tT or tT/tPSA and prostate cancer (OR=1.06, 95% CI, 0.84-1.33; OR=0.94, 95% CI, 0.70-1.27, respectively). The tT levels were not significantly different across Gleason score groups (p=0.553). In patients suspected of having prostate cancer the tT levels are not useful to improve the yielding of patient selection for prostatic biopsy or to predict cancer aggressiveness.
Autores principais:Botelho, Francisco
Outros Autores:Pina, Francisco; Figueiredo, Luís Pacheco; Cruz, Francisco; Lunet, Nuno
Assunto:Prostatic neoplasms Testosterone Diagnosis
Ano:2012
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso restrito
Instituição associada:Universidade do Minho
Idioma:inglês
Origem:RepositóriUM - Universidade do Minho
_version_ 1866877514129866752
author Botelho, Francisco
author2 Pina, Francisco
Figueiredo, Luís Pacheco
Cruz, Francisco
Lunet, Nuno
author2_role author
author
author
author
author_facet Botelho, Francisco
Pina, Francisco
Figueiredo, Luís Pacheco
Cruz, Francisco
Lunet, Nuno
author_role author
contributor_name_str_mv Universidade do Minho
country_str PT
creators_json_txt [{\"Person.name\":\"Botelho, Francisco\"},{\"Person.name\":\"Pina, Francisco\"},{\"Person.name\":\"Figueiredo, Luís Pacheco\"},{\"Person.name\":\"Cruz, Francisco\"},{\"Person.name\":\"Lunet, Nuno\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Universidade do Minho
datacite.creators.creator.creatorName.fl_str_mv Botelho, Francisco
Pina, Francisco
Figueiredo, Luís Pacheco
Cruz, Francisco
Lunet, Nuno
datacite.date.Accepted.fl_str_mv 2012-01-01T00:00:00Z
datacite.date.available.fl_str_mv 2015-02-05T14:34:24Z
datacite.date.embargoed.fl_str_mv 2015-02-05T14:34:24Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_16ec
datacite.subjects.subject.fl_str_mv Prostatic neoplasms
Testosterone
Diagnosis
datacite.titles.title.fl_str_mv Does baseline total testosterone improve the yielding of prostate cancer screening?
dc.contributor.none.fl_str_mv Universidade do Minho
dc.creator.none.fl_str_mv Botelho, Francisco
Pina, Francisco
Figueiredo, Luís Pacheco
Cruz, Francisco
Lunet, Nuno
dc.date.Accepted.fl_str_mv 2012-01-01T00:00:00Z
dc.date.available.fl_str_mv 2015-02-05T14:34:24Z
dc.date.embargoed.fl_str_mv 2015-02-05T14:34:24Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv https://hdl.handle.net/1822/33619
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv Elsevier
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.subject.none.fl_str_mv Prostatic neoplasms
Testosterone
Diagnosis
dc.title.fl_str_mv Does baseline total testosterone improve the yielding of prostate cancer screening?
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description Previous studies suggest an association between total testosterone (tT) and prostate cancer, but results are conflicting and it is not clear if accounting for the tT levels improves the yielding of patient selection for prostatic biopsy. We evaluated the potential for tT levels and the tT/total PSA (tPSA) ratio to be used as diagnostic tools for prostate cancer and its relation with cancer aggressiveness. We measured tT, tPSA and free PSA (fPSA) in fasting blood samples of 1570 subjects consecutively referred for prostate biopsy due to abnormal digital rectal examination and/or elevated tPSA levels. These values were compared between groups defined according to the pathological results of the biopsy. No significant difference was observed in tT levels when comparing cases with prostate cancer, high grade prostate intraepithelial neoplasia, pathological prostatitis, benign prostatic hyperplasia or no alteration (median: 4.26 versus 4.44 versus 4.31 versus 4.16 pg/mL, respectively; p=0.643). The tT/tPSA ratio had a better area under the curve than tT alone (0.62, 95% CI, 0.59-0.65 versus 0.50, 95% CI, 0.47-0.53), but worse than the f/tPSA ratio (0.70, 95% CI, 0.67-0.73). In multivariate analysis, using the median of distribution as cut-off no significant association was observed between tT or tT/tPSA and prostate cancer (OR=1.06, 95% CI, 0.84-1.33; OR=0.94, 95% CI, 0.70-1.27, respectively). The tT levels were not significantly different across Gleason score groups (p=0.553). In patients suspected of having prostate cancer the tT levels are not useful to improve the yielding of patient selection for prostatic biopsy or to predict cancer aggressiveness.
dirty 0
eu_rights_str_mv restrictedAccess
format article
fulltext.url.fl_str_mv https://prod-dspace.uminho.pt/bitstreams/dd5daf76-772f-499b-ba77-575ab8067669/download
id rum_623ad0cc2c6a4a2cc63b9ff7b2cda85e
identifier.url.fl_str_mv https://hdl.handle.net/1822/33619
instacron_str repositorium
institution Universidade do Minho
instname_str Universidade do Minho
language eng
network_acronym_str rum
network_name_str RepositóriUM - Universidade do Minho
oai_identifier_str oai:repositorium.uminho.pt:1822/33619
organization_str_mv urn:organizationAcronym:repositorium
person_str_mv Botelho, Francisco
Pina, Francisco
Figueiredo, Luís Pacheco
Cruz, Francisco
Lunet, Nuno
publishDate 2012
publisher.none.fl_str_mv Elsevier
reponame_str RepositóriUM - Universidade do Minho
repository_id_str urn:repositoryAcronym:rum
service_str_mv urn:repositoryAcronym:rum
spelling engElsevierporPrevious studies suggest an association between total testosterone (tT) and prostate cancer, but results are conflicting and it is not clear if accounting for the tT levels improves the yielding of patient selection for prostatic biopsy. We evaluated the potential for tT levels and the tT/total PSA (tPSA) ratio to be used as diagnostic tools for prostate cancer and its relation with cancer aggressiveness. We measured tT, tPSA and free PSA (fPSA) in fasting blood samples of 1570 subjects consecutively referred for prostate biopsy due to abnormal digital rectal examination and/or elevated tPSA levels. These values were compared between groups defined according to the pathological results of the biopsy. No significant difference was observed in tT levels when comparing cases with prostate cancer, high grade prostate intraepithelial neoplasia, pathological prostatitis, benign prostatic hyperplasia or no alteration (median: 4.26 versus 4.44 versus 4.31 versus 4.16 pg/mL, respectively; p=0.643). The tT/tPSA ratio had a better area under the curve than tT alone (0.62, 95% CI, 0.59-0.65 versus 0.50, 95% CI, 0.47-0.53), but worse than the f/tPSA ratio (0.70, 95% CI, 0.67-0.73). In multivariate analysis, using the median of distribution as cut-off no significant association was observed between tT or tT/tPSA and prostate cancer (OR=1.06, 95% CI, 0.84-1.33; OR=0.94, 95% CI, 0.70-1.27, respectively). The tT levels were not significantly different across Gleason score groups (p=0.553). In patients suspected of having prostate cancer the tT levels are not useful to improve the yielding of patient selection for prostatic biopsy or to predict cancer aggressiveness.application/pdfporDoes baseline total testosterone improve the yielding of prostate cancer screening?Botelho, FranciscoPina, FranciscoFigueiredo, Luís PachecoCruz, FranciscoLunet, NunoHostingInstitutionOrganizationalUniversidade do Minhoe-mailmailto:repositorium@usdb.uminho.ptrepositorium@usdb.uminho.ptISSNIsPartOf0959-8049DOIIsPartOf10.1016/j.ejca.2012.01.0252015-02-05T14:34:24Z20122015-01-30T16:35:40Z2012-01-01T00:00:00ZHandlehttps://hdl.handle.net/1822/33619http://purl.org/coar/access_right/c_16ecrestricted accessProstatic neoplasmsTestosteroneDiagnosis286643 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal articlehttp://purl.org/coar/access_right/c_16ecapplication/pdffulltexthttps://prod-dspace.uminho.pt/bitstreams/dd5daf76-772f-499b-ba77-575ab8067669/download
spellingShingle Does baseline total testosterone improve the yielding of prostate cancer screening?
Botelho, Francisco
Prostatic neoplasms
Testosterone
Diagnosis
status SINGLETON
subject.fl_str_mv Prostatic neoplasms
Testosterone
Diagnosis
title Does baseline total testosterone improve the yielding of prostate cancer screening?
title_full Does baseline total testosterone improve the yielding of prostate cancer screening?
title_fullStr Does baseline total testosterone improve the yielding of prostate cancer screening?
title_full_unstemmed Does baseline total testosterone improve the yielding of prostate cancer screening?
title_short Does baseline total testosterone improve the yielding of prostate cancer screening?
title_sort Does baseline total testosterone improve the yielding of prostate cancer screening?
topic Prostatic neoplasms
Testosterone
Diagnosis
topic_facet Prostatic neoplasms
Testosterone
Diagnosis
url https://hdl.handle.net/1822/33619
visible 1